US Stock MarketDetailed Quotes
PROK ProKidney
- 1.690
- +0.035+2.11%
Trading Nov 19 12:52 ET
216.27MMarket Cap-3129P/E (TTM)
1.735High1.500Low222.71KVolume1.650Open1.655Pre Close368.26KTurnover0.32%Turnover RatioLossP/E (Static)127.97MShares4.44052wk High-0.22P/B118.96MFloat Cap1.18052wk Low--Dividend TTM70.39MShs Float14.190Historical High--Div YieldTTM14.20%Amplitude1.120Historical Low1.653Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
ProKidney Stock Forum
ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting
Positive
FDA confirmation that PROACT 1 Phase 3 study could be sufficient for full regulatory approval
Accelerated approval pathway available with eGFR slope as surrogate endpoint
Strong cash position of $406.8 million, supporting operations into 2027
Reduced R&D expenses by $0.9 million year-over-year
Slight improvement...
SEC· 11 mins ago
ProKidney Announces Strategic Updates to Its Phase 3 Program to Accelerate Rilparencel’s Registrational Path to Potential Approval in the U.S. Believes Phase 3 Regen-016 (Proact 2) Trial Is Not Required for Initial U.S. Registration
ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
No comment yet